Results from a phase III randomized trial (ALSYMPCA) of radium-223 chloride, a first-in-class alpha-emitter, in patients with castration-resistant prostate cancer (CRPC) and bone metastases: overall survival benefit and safety profile

被引：0
|
作者：
O'Sullivan, J. M. [1 ]
Parker, C. [2 ]
Cross, A.
O'Bryan-Tear, C. G. [3 ]
Garcia-Vargas, J. [4 ]
Sartor, O. [5 ]
机构：
[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Algeta ASA, Oslo, Norway
[4] Bayer HealthCare Pharmaceut, Montville, NJ USA
[5] Tulane Canc Ctr, New Orleans, LA USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP689
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [1] Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Parker, Chris
    Heinrich, Daniel
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas David
    Syndikus, Isabel
    Cross, Andrew
    O'Bryan-Tear, C. Gillies
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [2] Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Kuczyk, M. A.
    Parker, C.
    Heinrich, D.
    O'Sullivan, J. M.
    Fossa, S. D.
    Chodacki, A.
    Demkow, T.
    Logue, J. P.
    Seke, M.
    Widmark, A.
    Kramer, M. W.
    Johannessen, D. C.
    Nilsson, S.
    Hoskin, P.
    Solberg, A.
    James, N. D.
    Syndikus, I
    Cross, A.
    O'Bryan-Tear, G.
    Garcia-Vargas, J. E.
    Sartor, A. O.
    ONKOLOGIE, 2012, 35 : 182 - 182
  • [3] Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
    Parker, C.
    Heinrich, D.
    O'Sullivan, J. M.
    Fossa, S.
    Chodacki, A.
    Demkow, T.
    Cross, A.
    Bolstad, B.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 3 - 3
  • [4] Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)
    Parker, C.
    Heinrich, D.
    Helle, S., I
    O'Sullivan, J. M.
    Fossa, S.
    Chodacki, A.
    Demkow, T.
    Logue, J.
    Seke, M.
    Widmark, A.
    Johannessen, D. C.
    Nilsson, S.
    Hoskin, P.
    Bottomley, D.
    Solberg, A.
    James, N. D.
    Syndikus, I
    Wedel, S. A.
    Kliment, J.
    Cross, A.
    O'Bryan-Tear, C. G.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E130 - U523
  • [5] Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Biodistribution/dosimetry compared to overall safety profile.
    Lewington, V.
    Parker, C.
    Hindorf, C.
    Flux, G.
    Chittenden, S.
    Sgouros, G.
    O'Bryan-Tear, G.
    Aksnes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Sartor, A. Oliver
    Heinrich, Daniel
    Helle, Svein Inge
    O'Sullivan, Joe M.
    Fossa, Sophie D.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John P.
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas David
    Syndikus, Isabel
    Vogelzang, Nicholas J.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Miller, K.
    Sartor, A. O.
    Heinrich, D.
    Helle, S., I
    O'Sullivan, J. M.
    Fossa, S. D.
    Chodacki, A.
    Demkow, T.
    Logue, J. P.
    Seke, M.
    Widmark, A.
    Johannessen, D. C.
    Nilsson, S.
    Hoskin, P.
    Solberg, A.
    James, N. D.
    Syndikus, I
    Vogelzang, N. J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2012, 35 : 238 - 239
  • [8] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
    Widmark, A.
    Helle, S. I.
    James, N.
    Larsson, A.
    Staudacher, K.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190
  • [9] RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES: A PHASE III RANDOMIZED TRIAL (ALSYMPCA)
    Sartor, Oliver
    Heinrich, Daniel
    Helle, Svein Inge
    O'Sullivan, Joe M.
    Chodacki, Ales
    Demkow, Tomasz
    Logue, John
    Seke, Mihalj
    Widmark, Anders
    Johannessen, Dag Clement
    Nilsson, Sten
    Hoskin, Peter
    Solberg, Arne
    James, Nicholas D.
    Syndikus, Isabel
    Vogelzang, Nicholas
    O'Bryan-Tear, Charles Gillies
    Garcia-Vargas, Jose
    Shan, Minghua
    Parker, Chris
    JOURNAL OF UROLOGY, 2012, 187 (04): : E279 - E279
  • [10] Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase HI Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases
    Sandler, H. M.
    Nilsson, S.
    Parker, C.
    Garcia-Vargas, J.
    Staudacher, K.
    Hoskin, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S3 - S4
12345